Welcome to UCL Cancer Institute
The UCL Cancer Institute is the hub for cancer research at University College London, one of the World's leading universities. The Institute draws together over 300 talented scientists who are working together to translate research discoveries into developing better, more effective therapies for cancers and improve outcomes for cancer patients. If you are thinking about postgraduate study with us, applications to our flagship MSc Cancer programme are open for the academic year 2017/18, or find our more about our postgraduate research.
News and features
A scientific team led by UCL has found a hotspot in ‘junk’ DNA that appears to be controlling how a nearby cancer-causing gene behaves, according to research published in the journal, Blood.
Published: Mar 20, 2017 5:29:56 PM
New research led by UCL has revealed how certain cancer cells are able to rewire the TRAIL cell signalling pathway to help promote tumour growth and avoid immune recognition. The findings, published in Molecular Cell, provide a compelling case for exploring the potential of blocking TRAIL as a treatment for some cancers.
Published: Mar 14, 2017 10:35:54 AM
Cholesterol-lowering statins used alongside chemotherapy have no effect on treatment outcomes for lung cancer patients, according to a new study published in the Journal of Clinical Oncology.
Published: Mar 3, 2017 5:32:55 PM
Scientists from UCL, the Wellcome Trust Sanger Institute, and the University of Cambridge have identified differences in transcriptional and epigenetic variation between immune cell types that could provide vital clues to understanding how these cells adapt and respond to changing environmental conditions. These findings will inform research into how this variation can be influenced to benefit patients with immune-related diseases such as type 1 diabetes and cancer.
Published: Mar 2, 2017 12:51:36 PM
Support our work
Help us to continue the research that will lead to the breakthroughs in cancer therapies that will benefit the lives of cancer patients.